The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS - Related Studies

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

This study has been completed.

Study NCT00002299. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cytomegalovirus Retinitis
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Cytomegalovirus Infections
		Immunologic Deficiency Syndromes
		Infection
		Retinitis

3	More general conditions related to this trial
		DNA Virus Infections
		Eye Diseases
		Eye Infections
		Eye Infections, Viral
		Herpesviridae Infections
		Immune System Diseases
		Lentivirus Infections
		Retinal Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Interferon beta-1b
		Ganciclovir

5	Additional drug interventions recognized in this trial
		Interferon Alfa-2b
		Interferon Type I, Recombinant
		Interferon-beta
		Interferons

6	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Infective Agents
		Antineoplastic Agents
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Hoffmann-La Roche